LOPRESSIDONE
Clinical safety rating
cautionComprehensive clinical and safety monograph for LOPRESSIDONE (LOPRESSIDONE).
Lopressidone is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors, with higher affinity for 5-HT2A than D2, and also blocks alpha1-adrenergic and H1 histamine receptors.
| Metabolism | Primarily hepatic via CYP3A4 and CYP2D6; also involves conjugation and minor CYP1A2 contribution. |
| Excretion | Renal: ~60% (as unchanged drug); Fecal: ~30% (as metabolites); Biliary: minor (<5%). |
| Half-life | 12-15 hours; allows once-daily dosing, but steady-state reached in ~3-5 days. |
| Protein binding | 98% bound to albumin and alpha-1 acid glycoprotein. |
| Volume of Distribution | 7-9 L/kg; extensive tissue distribution, including CNS. |
| Bioavailability | Oral: 45-60% due to first-pass metabolism; IM: 90-100%. |
| Onset of Action | Oral: 2-4 hours; IV: 5-10 minutes; peak effect at 4-6 weeks for antipsychotic efficacy. |
| Duration of Action | 24 hours after single oral dose; sustained with daily dosing; therapeutic effect persists for days after cessation. |
| Molecular Weight | 466.4 |
Oral: 5 mg twice daily, titrate as tolerated up to 20 mg twice daily. Maximum 40 mg per day.
| Dosage form | CAPSULE |
| Renal impairment | GFR 30-89 mL/min: No adjustment. GFR <30 mL/min: Not recommended due to lack of data. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B or C: Contraindicated due to significant hepatic metabolism. |
| Pediatric use | Not approved for use in pediatric patients. |
| Geriatric use | Initiate at 2.5 mg twice daily; titrate slowly due to increased risk of orthostatic hypotension and falls. Maximum 20 mg per day. |
| 1st trimester | Limited data; animal studies show fetal abnormalities, but no adequate human studies. Use only if benefit outweighs risk. |
| 2nd trimester | Risk of extrapyramidal symptoms and withdrawal in neonates. Consider alternative agents. |
| 3rd trimester | Risk of extrapyramidal symptoms and withdrawal in neonates. Consider alternative agents. |
Clinical note
Comprehensive clinical and safety monograph for LOPRESSIDONE (LOPRESSIDONE).
| Placental transfer | Crosses placenta; detectable in cord blood at concentrations ~30% of maternal plasma. |
| Breastfeeding | Excreted into breast milk in low concentrations; monitor infant for sedation, feeding difficulties, and extrapyramidal signs. Use with caution. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimester: No known fetal risks at therapeutic doses. |
| Fetal Monitoring | Monitor maternal blood pressure and heart rate; fetal growth assessment via ultrasound in third trimester; neonatal monitoring for sedation and respiratory depression if used near term. |
| Fertility Effects | Reversible decrease in sperm motility and concentration in males; menstrual irregularities in females; no permanent impact on fertility. |
■ FDA Black Box Warning
Increased mortality in elderly patients with dementia-related psychosis.
| Serious Effects |
Known hypersensitivity to lurasidone or any componentConcomitant use with strong CYP3A4 inducers (e.g., carbamazepine, rifampin) or strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin)
| Precautions | Cerebrovascular adverse events in elderly with dementia, Neuroleptic malignant syndrome (NMS), Tardive dyskinesia, Metabolic changes (hyperglycemia, dyslipidemia, weight gain), Hyperprolactinemia, Orthostatic hypotension, Seizures, Leukopenia/neutropenia/agranulocytosis, QT interval prolongation, Body temperature dysregulation, Dysphagia, Suicidal thoughts/behaviors |
| Food/Dietary | Grapefruit and grapefruit juice may increase serum levels of LOPRESSIDONE and risk of toxicity. Alcohol may worsen CNS depression and hypotension. High-fat meals may enhance absorption. Avoid concurrent use with St. John's wort as it may reduce efficacy. Maintain adequate hydration to prevent constipation. |
| Clinical Pearls | LOPRESSIDONE (a fictional atypical antipsychotic) requires ECG monitoring for QTc prolongation at baseline and after dose escalation. Titrate slowly to minimize orthostatic hypotension. Avoid use in patients with dementia-related psychosis due to increased mortality. Monitor for extrapyramidal symptoms, especially in elderly. Use with caution in patients with diabetes or hyperlipidemia as it may worsen metabolic parameters. Administer with food to reduce nausea. Renal dose adjustment needed for CrCl <30 mL/min. |
| Patient Advice | Take this medication exactly as prescribed, with food to reduce stomach upset. · Do not stop taking this drug suddenly; consult your doctor before discontinuing. · Rise slowly from sitting or lying to prevent dizziness from low blood pressure. · Report any irregular heartbeat, fainting, or severe dizziness immediately. · Avoid alcohol and grapefruit juice while on this medication. · This drug may cause drowsiness; do not drive or operate machinery until you know how it affects you. · Contact your doctor if you experience muscle stiffness, fever, confusion, or abnormal movements. |
Loading safety data…